RedHill Biopharma to Host Second Quarter Financial Results and Business Highlights Conference Call and Webcast on August 13, 2020

TEL-AVIV, Israel and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its second quarter 2020 financial results and business highlights on Thursday, August 13, 2020.

The Company will host a conference call and webcast on Thursday, August 13, 2020 at 8:30 a.m. EDT, during which it will present key highlights for the second quarter of 2020, including:

• Financial performance for the quarter ended June 30, 2020
• Commercial activities status, including U.S. promotion of Movantik, Talicia and Aemcolo
• The ongoing global Phase 2/3 development program with opaganib for COVID-19
• Pipeline progress, including the upcoming initiation of a pivotal Phase 3 study with RHB-204 for first-line pulmonary nontuberculous mycobacteria (NTM) infections

The webcast and slides will be broadcasted live on the Company's website: http://ir.redhillbio.com/events and available for replay following the call for 30 days.

To participate in the conference call, please dial one of the following numbers 15 minutes prior to the start of the call: United States: [phone]; International: [phone] and Israel: [phone]; the access code for the call is: 3681547.

About RedHill Biopharma      
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. RedHill promotes the gastrointestinal drugs Movantikfor opioid-induced constipation in adults¹, Talicia for the treatment of Helicobacter pylori (H. pylori) infection in adults² and Aemcolo for the treatment of travelers’ diarrhea in adults³. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (ii) opaganib (Yeliva), a first-in-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and ongoing Phase 2 studies for prostate cancer and cholangiocarcinoma; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (iv) RHB-102 (Bekinda), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) RHB-106, an encapsulated bowel preparation, and (vi) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases and currently also being evaluated for COVID-19. More information about the Company is available at www.redhillbio.com.